Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain

S. Grau, M. Salavert, J. Carlos Pozo Laderas, M. García Vargas, J. A. Barrueta, N. Mir

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

Background: Candidaemia and invasive Candida infections can cause patient death and are expensive. Anidulafungin, a newly-licensed candin, has proven effective in treating candidaemia. Our study evaluates the cost-effectiveness of anidulafungin compared with fluconazole, the current standard of care, for treating invasive candidiasis and candidaemia in Spain. Methods: A decision tree model from the hospital perspective was constructed to examine the cost-effectiveness of anidulafungin compared with fluconazole in treating confirmed candidaemia. Treatment success, patient treatment patterns, and patient survival were based on the results from a randomised, double-blind multicentre trial (Reboli et al., 2007 [41]). Only in-hospital (2011 €) direct costs per-patient obtained from a Spanish national database were considered. Renal toxicity probabilities and costs were extracted from the published literature. The incremental cost per successfully treated patient was calculated. One-way sensitivity analyses were performed to test model robustness. Results: The percentage of successfully treated patients was higher with anidulafungin than with fluconazole (74% versus 57%). Treatment with anidulafungin resulted in higher antifungal drug costs (5991. € versus 3149. €) but lower overall costs (40. 047. € versus 41. 350. €) due to reductions in other medical costs. Univariate sensitivity analyses showed that anidulafungin was the most cost-effective. Conclusions: Anidulafungin demonstrated improved clinical efficacy versus fluconazole in treating confirmed candidaemia. Despite increased drug costs, treating confirmed candidaemia with anidulafungin is a cost-effective strategy. © 2013 Elsevier Masson SAS.
Original languageEnglish
Pages (from-to)155-163
JournalJournal de Mycologie Medicale
Volume23
Issue number3
DOIs
Publication statusPublished - 1 Sep 2013

Keywords

  • Anidulafungin
  • Antifungal
  • Candidaemia
  • Cost-effectiveness analysis
  • Fluconazole
  • Invasive candidiasis

Fingerprint Dive into the research topics of 'Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain'. Together they form a unique fingerprint.

Cite this